Angela Schulz
Dr. med.
Angela Schulz
  • Funktionsoberärztin
  • Facharzt für Kinder- und Jugendmedizin
Arbeitsbereich

Standort

O45 , 1. Etage
Sprachen
Deutsch (Muttersprache)
Englisch
Französisch

Fachgebiete

Tätigkeitsschwerpunkte

Auszeichnungen

Mitgliedschaften

Publikationen

Zurück
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2009
  • 2006
  • 2004
  • 2000
Vor

Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study
Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, Pagovich O, Kosofsky B, Yohay K, Downs M, Slasor P, Ajayi T, Crystal R, Kohlschütter A, Sondhi D, Schulz A
The Lancet. Child & adolescent health. 2018;2(8):582-590.

Autophagic vacuolar myopathy is a common feature in CLN3 disease
Radke J, Koll R, Gill E, Wiese L, Schulz A, Kohlschütter A, Schuelke M, Hagel C, Stenzel W, Goebel H
Ann Clin Transl Neurol. 2018.

Study of Intraventricular Cerliponase Alfa for CLN2 Disease
Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke J, Cahan H, Slasor P, Jacoby D, Kohlschütter A
NEW ENGL J MED. 2018;378(20):1898-1907.

Neurodegenerative Erkrankungen des Kindesalters
Schulz A, Nickel M
MED GENET-BERLIN. 2018;30(2):231-237.

An Adapted Clinical Measurement Tool for the Key Symptoms of CLN2 Disease
Wyrwich K, Schulz A, Nickel M, Slasor P, Ajayi T, Jacoby D, Kohlschütter A
J INHERIT METAB DIS. 2018;6:1-7.

Treatment of brain disease in the mucopolysaccharidoses
Scarpa M, orchard p, Schulz A, Dickson P, Haskins M, Escolar M, Giugliani R
MOL GENET METAB. 2017;122S:25-34.

Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5
Simonati A, Williams R, Nardocci N, Laine M, Battini R, Schulz A, Garavaglia B, Moro M, Pezzini F, Santorelli F
DEV MED CHILD NEUROL. 2017;59(8):815-821.

Management Strategies for CLN2 Disease
Williams R, Adams H, Blohm M, Cohen-Pfeffer J, de Los Reyes E, Denecke J, Drago K, Fairhurst C, Frazier M, Guelbert N, Kiss S, Kofler A, Lawson J, Lehwald L, Leung M, Mikhaylova S, Mink J, Nickel M, Shediac R, Sims K, Specchio N, Topcu M, von Löbbecke I, West A, Zernikow B, Schulz A
PEDIATR NEUROL. 2017;69:102-112.

Novel morphological macular findings in juvenile CLN3 disease
Dulz S, Wagenfeld L, Nickel M, Richard G, Schwartz R, Bartsch U, Kohlschütter A, Schulz A
BRIT J OPHTHALMOL. 2016;100(6):824-8.

Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis
Fietz M, AlSayed M, Burke D, Cohen-Pfeffer J, Cooper J, Dvořáková L, Giugliani R, Izzo E, Jahnová H, Lukacs Z, Mole S, Noher de Halac I, Pearce D, Poupetova H, Schulz A, Specchio N, Xin W, Miller N
MOL GENET METAB. 2016;119(1-2):160-7.

Considering Valproate as a Risk Factor for Rapid Exacerbation of Complex Movement Disorder in Progressed Stages of Late-Infantile CLN2 Disease
Johannsen J, Nickel M, Schulz A, Denecke J
NEUROPEDIATRICS. 2016;47(3):194-6.

CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis)
Kohlschütter A, Schulz A
PEDIATR ENDOCRINOL REV. 2016;13 (Suppl 1):682-8.

Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease Progression
Löbel U, Sedlacik J, Nickel M, Lezius S, Fiehler J, Nestrasil I, Kohlschütter A, Schulz A
AM J NEURORADIOL. 2016;37(10):1938 – 1943.

Phenotyping heterozygous carriers of juvenile neuronal ceroid lipofuscinosis with CLN3 mutations
Bergholz R, Kohlschütter A, Schulz A, Hubert W, Rüther K
GRAEF ARCH CLIN EXP. 2015;253(8):1245-1250.

Lysoplex: An efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway
Di Fruscio G, Schulz A, De Cegli R, Savarese M, Mutarelli M, Parenti G, Banfi S, Braulke T, Nigro V, Ballabio A
AUTOPHAGY. 2015;11(6):928-38.

Ethical issues with artificial nutrition of children with degenerative brain diseases
Kohlschütter A, Riga C, Crespo D, Torres J, Penchaszadeh V, Schulz A
BBA-MOL BASIS DIS. 2015;1852(7):1253-1256.

Reprint of "Ethical issues with artificial nutrition of children with degenerative brain diseases"
Kohlschütter A, Riga C, Crespo D, Torres J, Penchaszadeh V, Schulz A
BBA-MOL BASIS DIS. 2015;1852(10 Pt B):2312-5.

Demenzerkrankungen bei Kindern und Jugendlichen
Kohlschütter A, Schulz A, Bley A, Nickel M, Richterich A
Päd Praxis. 2015;83:561-570.

Epilepsy in Neuronal Ceroid Lipofuscinoses (NCL)
Kohlschütter A, Schulz A, Denecke J
J Pediatr Epilepsy. 2014;3:199-206.

Brain iron quantification by MRI in mitochondrial membrane protein-associated neurodegeneration under iron-chelating therapy
Löbel U, Schweser F, Nickel M, Deistung A, Grosse R, Hagel C, Fiehler J, Schulz A, Hartig M, Reichenbach J, Kohlschütter A, Sedlacik J
Ann Clin Transl Neurol. 2014;1(12):1041-6.

Unexplained Loss of Vision in a Child:: Consider Bilateral Primary Optic Nerve Sheath Meningioma
Nickel M, Löbel U, Holst B, Kammler G, Matschke J, Schulz A, Kohlschütter A
NEUROPEDIATRICS. 2014;45(5):321-4.

Quantitative t2 measurements in juvenile and late infantile neuronal ceroid lipofuscinosis.
Bravo A, Forkert N, Schulz A, Löbel U, Fiehler J, Ding X, Sedlacik J, Rosenkranz M, Goebell E
CLIN NEURORADIOL. 2013;23(3):189-196.

NCL Disorders: Frequent Causes of Childhood Dementia
Schulz A, Kohlschütter A
Iran J Child Neurol. 2013;7(1):1-8.

NCL diseases - clinical perspectives
Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R
BBA-MOL BASIS DIS. 2013;1832(11):1801-6.

Novel mutations consolidate KCTD7 as a progressive myoclonus epilepsy gene
Kousi M, Anttila V, Schulz A, Calafato S, Jakkula E, Riesch E, Myllykangas L, Kalimo H, Topçu M, Gökben S, Alehan F, Lemke J, Alber M, Palotie A, Kopra O, Lehesjoki A
J MED GENET. 2012;49(6):391-9.

Neuronale Zeroidlipofuszinosen (NCL) - Metabolische Demenzkrankheiten im Kindesalter
Schulz A, Kohlschütter A
MONATSSCHR KINDERH. 2012;160:734-741.

CLN2
Chang M, Cooper J, Davidson B, van Diggelen O, Elleder M, Goebel H, Golabek A, Kida E, Kohlschütter A, Lobel P, Mole S, Schulz A, Sleat D, Warburton M, Wisniewski K
2011. The Neuronal Ceroid Lipofuscinoses (Batten Disease). Oxford University Press, .

Analysis of Potential Biomarkers and Modifier Genes Affecting the Clinical Course of CLN3 Disease.
Lebrun A, Moll-Khasrawi P, Pohl S, Makrypidi G, Storch S, Kilian D, Streichert T, Otto B, Mole S, Ullrich K, Cotman S, Kohlschütter A, Braulke T, Schulz A
MOL MED. 2011;17(11-12):1253-1261.

Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship.
Lebrun A, Storch S, Rüschendorf F, Schmiedt M, Kyttälä A, Mole S, Kitzmüller C, Saar K, Mewasingh L, Boda V, Kohlschütter A, Ullrich K, Braulke T, Schulz A
HUM MUTAT. 2009;30(5):651-661.

The CLN9 protein, a regulator of dihydroceramide synthase.
Schulz A, Mousallem T, Venkataramani M, Persaud-Sawin D, Zucker A, Luberto C, Bielawska A, Bielawski J, Holthuis J, Jazwinski S, Kozhaya L, Dbaibo G, Boustany R
J BIOL CHEM. 2006;281(5):2784-2794.

Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant.
Schulz A, Dhar S, Rylova S, Dbaibo G, Alroy J, Hagel C, Artacho I, Kohlschütter A, Lin S, Boustany R
ANN NEUROL. 2004;56(3):342-350.

Selective effect of tumor necrosis factor on transformed versus nontransformed cells: nonselective signal recognition but differential target cell response.
Schulz A, Bauer G
ANTICANCER RES. 2000;20(5):3435-3442.

Synergistic action between tumor necrosis factor-alpha and transforming growth factor type-beta: consequences for natural antitumor mechanisms.
Schulz A, Bauer G
ANTICANCER RES. 2000;20(5):3443-3448.

Letzte Aktualisierung aus dem FIS: 14.11.2018 - 00:02 Uhr